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Purpose: To investigate the impact of obstructive sleep apnea (OSA) on endothelial repair 
capacity and apoptosis in the absence of potentially confounding factors including obesity.
Patients and methods: Sixteen patients with a body mass index 30 and newly diagnosed 
OSA and 16 controls were studied. Circulating levels of endothelial progenitor cells, a marker 
of endothelial repair capacity, and endothelial microparticles, a marker of endothelial apoptosis, 
were quantified before and after four-week therapy with continuous positive airway pressure 
(CPAP). Endothelial cell apoptotic rate was also quantified in freshly harvested venous endo-
thelial cells. Vascular reactivity was measured by flow-mediated dilation.
Results: Before treatment, endothelial microparticle levels were greater and endothelial progeni-
tor cell levels were lower in patients with OSA than in controls (P  0.001 for both). Levels of 
endothelial microparticles and progenitors cells were inversely related (r = -0.67, P  0.001). 
Endothelial progenitor cell levels increased after effective treatment (P = 0.036).
Conclusions: In the absence of any co-morbid conditions including obesity, OSA alone impairs 
endothelial repair capacity and promotes endothelial apoptosis. These early endothelial alterations 
may underlie accelerated atherosclerosis and increased cardiovascular risk in OSA.
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Introduction
Accelerated atherosclerosis and cardiovascular morbidity may result from 
continuous damage to the vascular endothelium in patients with obstructive sleep 
apnea (OSA).1–8 Patients with coronary artery disease (CAD) exhibit increased 
rates of endothelial apoptosis and reduced endothelial repair capacity that con-
tribute to continuous endothelial damage.9,10 Whether OSA independently affects 
endothelial apoptosis and repair capacity remains controversial.11–17 Increased 
rate of endothelial apoptosis has been reported in patients with OSA by some 
investigators while others have reported similar levels of apoptotic microparticles 
in patients with OSA and controls.11,12,15–17 The data regarding endothelial repair 
capacity in patients with OSA are also controversial: Endothelial repair capacity 
was reported to be intact by some investigators and reduced by others.8,13,14 Of note 
the presence of co-morbid conditions which are frequently associated with OSA 
and known to affect the vascular endothelium was not systematically excluded in 
all above mentioned studies.
Accordingly, the present study was undertaken to determine the effects of OSA on 
endothelial apoptosis and repair capacity in the absence of any conditions known to 
affect the vascular endothelium. In particular, we exclusively studied nonobese patients Vascular Health and Risk Management 2009:5 910
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with OSA as obesity alone affects the vascular endothelium.18 
We hypothesized that the rate of endothelial apoptosis is 
greater and repair capacity lower in patients with OSA than 
in healthy controls matched for age, gender and body mass 
index (BMI), and that continuous positive airway pressure 
(CPAP) therapy decreases the rate of endothelial apoptosis 
while improving endothelial repair capacity. The rate of 
endothelial apoptosis was quantified by measuring: a) levels 
of circulating endothelial microparticles (EMP) that are shed 
directly from apoptotic endothelial cells, and b) the rate of 
apoptotic nuclei in freshly harvested venous endothelial 
cells. Endothelial repair capacity was assessed by quantifying 
solely immature endothelial cells.19–25 Lastly, flow-mediated 
dilation was assessed as the functional correlate of endothe-
lial apoptosis and repair capacity in OSA. Measurements 
were repeated after CPAP therapy for four weeks.
Methods
study population
Patients who were evaluated in the Sleep Disorders Center 
at the New York Presbyterian Hospital for evaluation of 
sleep-disordered breathing between March 2006 and April 
2009 were prospectively screened for the study. Obesity was 
defined as BMI  30. Patients with newly diagnosed OSA 
defined as an apnea–hypopnea index (AHI) of five or more 
obstructive events per hour of sleep and BMI  30 who were 
free of conditions known to affect the vascular endothelium 
were eligible for the study. Patients with dyslipidemias, 
diabetes mellitus, cardiovascular, neurological, pulmonary, 
and renal diseases were ineligible for the study. Former and 
current smokers and patients receiving medications or nutri-
tional supplements were also ineligible.
Controls were nonsmoking healthy subjects who were not 
receiving medications or nutritional supplements. Control 
subjects were recruited from the community through advertis-
ing and were matched to patients for gender, age (within four 
years), and BMI (within 15%). Six patients with OSA in the 
present study were included in the previous study conducted 
in our Sleep Disorders Center.8 The Columbia University 
Committee on Human Research approved the study. All study 
participants signed a written informed consent.
study protocol
Nocturnal polysomnography was performed in all study 
participants as previously described.8 AHI was defined as the 
number of obstructive apnea plus hypopnea episodes per hour 
of sleep. Endothelial cells harvesting, blood sample collection, 
and flow-mediated dilation (FMD) were performed between 
9:00 and 11:00 AM within 48 hours of polysomnography while 
study participants were in a fasting state. All experimental 
procedures were repeated after a four-week treatment period 
in all OSA patients. Adherence with CPAP was defined as 
CPAP use 4 hours daily.1 Adherence was assessed by using 
CPAP device with compliance software.
Harvesting and immunofluorescence  
for endothelial cell apoptosis
A 20-gauge angiocath was inserted into a forearm vein. Under 
sterile conditions, three J-shaped vascular guide wires (Arrow, 
Reading, PA) were sequentially advanced into the vein up 
to 10 cm. Tips of the wires were removed and washed in 
endothelial cell dissociation buffer kept at 4 °C. Endothelial 
cells were recovered by centrifugation and fixed with 3.7% 
formaldehyde in phosphate-buffered saline (PBS) for 10 min, 
washed twice with PBS, transferred to poly-l-lysine coated 
slides (Sigma, St. Louis, MO), and air-dried at 37 °C. The 
slides were stored at -80 °C until analyzed. Apoptotic cell 
nuclei were identified using in situ apoptosis peroxidase detec-
tion kit, the terminal deoxynucleotide transferase-mediated 
dUTP nick-end labeling (TUNEL). (Details regarding immu-
nofluorescence can be found in the Data Supplement).
Flow cytometry for circulating 
endothelial progenitor cells and  
apoptotic microparticles
EPC and EMP were quantified in venous blood by flow 
cytometry. EPC were defined as cells positive for monoclo-
nal antibodies against human KDR (kinase insert domain 
receptor), CD34, and CD133 (Figures 1A and 1B in the Data 
Supplement).19,22–25 EMP were defined as particles 1.5 µm 
in size positive for monoclonal antibodies against CD31 and 
negative for CD42b (Figure 2A and 2B in the Data Supple-
ment).26 (Details regarding flow cytometry can be found in 
the Data Supplement).
Brachial artery flow-mediated dilation
Vascular reactivity of the brachial artery was assessed in the 
contra-lateral arm to the endothelial harvesting site by FMD 
according to the guidelines of the International Brachial 
Artery Reactivity Task Force.27 (Details regarding FMD can 
be found in the Data Supplement).
statistical analysis
Continuous data are presented as mean ± standard deviation 
or median (interquartile range). Categorical data are Vascular Health and Risk Management 2009:5 911
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presented as percentage. To determine whether endothelial 
apoptosis and repair capacity differ between patients with 
OSA and controls, EMP and EPC levels were compared 
between groups using Wilcoxon rank sum tests and Fisher 
exact tests. To determine whether CPAP therapy affects EMP 
and EPC, we compared these measures before and after 
CPAP therapy using Wilcoxon signed rank tests. Statistical 
significance was assumed when null hypothesis could be 
rejected at P  0.05. Statistical analysis was performed 
with the use of SAS software (version 9.1; SAS Institute, 
Cary, NC).
Results
Sixteen patients with OSA and 16 control subjects were 
studied. The clinical and laboratory characteristics of 
study participants are summarized in Table 1. Patients and 
control subjects were similar regarding age, gender, BMI, 
systemic blood pressure, fasting blood glucose and total 
cholesterol levels. OSA patients had significantly lower 
arterial oxyhemoglobin saturation (SaO2) nadir during 
sleep and had more daytime sleepiness as measured by 
Epworth Sleepiness Scale than control subjects. Control 
subjects had an AHI  5 and spent no time during sleep 
with SaO2  90%.
endothelial apoptosis and repair  
capacity at baseline
Before treatment, levels of circulating EPC, a marker of 
endothelial repair capacity, were significantly lower and levels 
of circulating EMP, a marker of endothelial apoptosis, were 
significantly greater in patients with OSA than in controls 
(Figures 1A and 1B). Apoptotic nuclei in harvested venous 
endothelial cells were not detectable in all specimens obtained 
from patients with OSA and controls. Levels of circulating 
EMP and EPC were inversely related in the entire cohort 
(Figure 2).
effects of cPAP therapy on endothelial 
apoptosis and repair capacity
Eight patients used CPAP for four weeks and eight patients 
declined CPAP therapy due to discomfort. The average 
daily use of CPAP was 5.8 ± 2.1 hours (range 2–8 hours). 
Seven patients used CPAP  4 hours daily for an average of 
6.4 ± 1.5 hours. The one remaining patient used CPAP for 
an average of two hours daily. Age, BMI, AHI, SaO2 nadir, 
t  SaO2 90%, daytime sleepiness, blood pressure, fasting 
glucose and total cholesterol levels as well as baseline 
EMP and EPC levels were similar in patients who accepted 
CPAP and patients who declined CPAP. Body weight and 
systolic and diastolic blood pressure remained unchanged 
during CPAP therapy.
CPAP therapy significantly increased EPC levels and 
tended to decrease EMP levels in patients with OSA com-
pared with their baseline values (Figures 1C and 1D). After 
effective treatment (CPAP  4 hours daily), EPC levels 
were similar in patients with OSA and controls (P = 0.92). 
Levels of EMP and EPC were unchanged in patients who 
declined CPAP and in one patient who used CPAP  4 hours 
daily. Apoptotic nuclei in harvested venous endothelial 
cells remained undetectable in all specimens obtained from 
adherent and nonadherent OSA patients.
Table 1 Baseline characteristics of patients with obstructive sleep apnea and control subjects
OSA patients 
(n = 16)
Control subjects 
(n = 16)
P value
Age (years) 36 ± 9 36 ± 11 ns
gender (% female) 44 50 ns
Body mass index (kg/m2) 27 ± 2 26 ± 3 ns
Apnea–Hypopnea index (events/h of sleep) 22 ± 24 0.1 ± 0.5 0.001
saO2 nadir (%) 88 ± 5 97 ± 1 0.001
t  saO2 90% (% of the total sleep time)a 1.4 ± 2.6 0 ± 0 0.001
epworth sleepiness scale score 12 ± 5 4 ± 3 0.001
systolic blood pressure (mm Hg) 118 ± 13 120 ± 10 ns
Diastolic blood pressure (mm Hg) 71 ± 10 73 ± 10 ns
Fasting glucose (mg/dL) 90 ± 16 87 ± 10 ns
Total cholesterol (mg/dL) 183 ± 56 188 ± 45 ns
Notes: Data are presented as mean ± standard deviation or %. aTime spent below saO2 of 90% during sleep.
Abbreviations: NS, not significant; OSA, obstructive sleep apnea; SaO2, arterial oxyhemoglobin saturation.Vascular Health and Risk Management 2009:5 912
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Figure 1 Levels of circulating endothelial progenitor cells (ePc) and apoptotic microparticles (eMP) in healthy controls and patients with obstructive sleep apnea (OsA) before 
and after treatment with continuous positive airway pressure (cPAP). Baseline levels of ePc were lower in OsA patients (n = 16) than in controls (n = 16) A) while levels of 
eMP were greater B). Levels of EPC increased significantly C) while levels of eMP tended to decreased D) when patients adhered with cPAP  4 hours daily (n = 7).
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Markers of endothelial apoptosis and 
repair capacity and flow-mediated dilation
Baseline brachial artery FMD, an indirect marker of 
endothelial nitric oxide-mediated reactivity, was lower 
in patients with OSA than in controls: 3.6 ± 2.6 vs 
9.1%  ±  4.5%,  (P  =  0.004). Effective treatment (CPAP  4 hours 
daily) tended to increase FMD (3.3 ± 2.1 vs 7.4% ± 3.9%, 
P = 0.06). In the absence of effective CPAP treatment, 
FMD remained unchanged. No differences in the resting 
brachial diameter and percent reactive hyperemia after 
cuff deflation were observed between patients with OSA 
and controls. Baseline circulating EMP levels were 
inversely related to FMD (Spearman correlation coef-
ficient adjusted for BMI = -0.43, P = 0.02) (Figure 3). 
Baseline circulating EPC levels did not correlate with 
FMD (r = 0.30, P = 0.13).
Discussion
The present data indicate that OSA independently promotes 
vascular endothelial apoptosis and impairs endothelial repair 
capacity. Effective CPAP therapy improves endothelial repair 
capacity. Enhanced endothelial apoptosis and impaired repair 
capacity may hasten the progression of atherosclerosis and 
thereby the development of hypertension, ischemic stroke or 
myocardial ischemia.
endothelial apoptosis in OsA
Elevated circulating EMP levels in otherwise healthy 
patients with OSA when compared to controls are strong 
evidence for enhanced endothelial apoptosis in OSA. The 
significant correlation between circulating EMP levels and 
endothelium-dependent vasodilation suggests that enhanced 
endothelial apoptosis results in endothelial damage thereby Vascular Health and Risk Management 2009:5 913
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depressing vascular endothelial function. The small number 
of venous endothelial cells that could be studied for apoptosis 
(100–150) most likely accounts for our inability to demon-
strate apoptosis in harvested endothelial cells by TUNEL 
assay. Direct demonstration of apoptosis will require harvest-
ing considerably more endothelial cells than we did in view 
of the relatively low endothelial apoptotic rate.28
Endothelial cell-derived apoptotic microparticles 
are directly shed from mature endothelial cells during 
apoptosis. Levels of circulating EMP inversely correlate 
with endothelium-dependent dilation in patients with CAD.9 
Elevated levels of circulating EMP have been reported in 
obese women who were not systematically evaluated for 
OSA.29 Considering a high prevalence of OSA in obesity, 
unrecognized OSA may have contributed to increased rate 
of endothelial apoptosis.29 Repetitive episodes of hypoxia/
reoxygenation, such as observed with transient cessation of 
breathing in OSA, may promote endothelial apoptosis by 
activating cell death receptors and mitochondria-dependent 
apoptotic pathways.30,31 Elevated circulating EMP levels also 
directly affect the vascular endothelium.32,33 Exposure of rat 
aortic rings to increasing concentrations of isolated EMP 
derived from cultured human endothelial cells or patients 
with myocardial ischemia alters endothelium-dependent 
vasodilation and nitric oxide production while simultane-
ously increasing superoxide production.32,34 Increased 
concentrations of EMP also impair angiogenesis in vitro.32 
When isolated from atherosclerotic plaques during carotid 
endarterectomy, EMP are highly thrombogenic and promote 
plaque formation and propagation.35
Elevated levels of circulating EMP in nonobese patients 
with OSA who are free of overt cardiovascular diseases 
strongly suggest that OSA alone promotes endothelial 
apoptosis. Increased levels of circulating EMP may underlie 
altered endothelial function and coagulation homeostasis 
in OSA.
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Figure 2 Relation between endothelial apoptotic rate and endothelial repair capacity in obstructive sleep apnea (OsA). Levels of circulating endothelial progenitor cells (ePc) and 
microparticles (EMP) are inversely related at baseline (Spearman correlation coefficient r = -0.67, P  0.001). OsA patients (closed circles), healthy controls (open circles).Vascular Health and Risk Management 2009:5 914
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Figure 3 Relation between endothelial apoptotic rate and flow-mediated dilation in obstructive sleep apnea (OSA). Levels of circulating apoptotic microparticles correlate 
inversely with flow-mediated dilation in OSA (Spearman correlation coefficient adjusted for body mass index r = -0.43, P = 0.02). OsA patients (closed circles), healthy 
controls (open circles).
endothelial repair capacity in OsA
Intact endothelial repair capacity may offset the progressive 
loss of endothelial cells due to repetitive hypoxia/reoxygen-
ation in patients with OSA. Expression of CD34, CD133 and 
KDR is currently required for EPC identification by most 
investigators.19,22 A recent controversial report has questioned 
whether CD34+, CD133+, and VEGFR2+ cells are endothelial 
or hematopoietic progenitors.36 Independently from their 
controversial capacity to form vessel-like structures in vitro, 
CD34+, CD133+, and VGEFR2+ undoubtedly restore endo-
thelial lining in vivo.37–40 A decreased level of such cells in 
OSA is consistent with reduced endothelial repair capacity 
that can be reversed by CPAP therapy.
Reduced EPC levels compromise endothelial repair 
by reducing availability of angiogenic growth factors and 
the pool of endothelial cells with proliferative capacity.22 
Reduced EPC level and activity are associated with impaired 
endothelial function and increased risk for vascular events in 
patients with CAD.10,41 Mobilization of EPC from the bone 
marrow entails adequate NO production that is reduced in 
patients with OSA.6–8,42 Reduced circulating EPC levels limit 
further NO production since EPC are an important source of 
NO production at the site of ischemia/reperfusion induced 
endothelial injury.43 The inverse correlation between circulat-
ing levels of EMP and EPC supports the view that enhanced 
endothelial apoptosis may exhaust the repair capacity of the 
vascular endothelium in OSA thereby resulting in continuous 
endothelial damage.
The effect of treatment for OsA on 
endothelial apoptosis and repair capacity
Adherence with CPAP therapy 4 hours nightly for four 
weeks exerted beneficial effects on endothelial repair capacity 
but did not significantly affect endothelial apoptosis or Vascular Health and Risk Management 2009:5 915
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FMD. Endothelial apoptosis appears to be a rare event in 
both patients with OSA and controls. Small number of OSA 
patients who adhered with CPAP therapy may have contrib-
uted to the lack of significant difference between baseline 
and post-CPAP measurements of endothelial apoptosis and 
FMD. The beneficial effects of CPAP therapy on endothelial 
repair capacity and apoptosis need to be confirmed in a larger 
study than the present one that will include multiple centers 
and randomized allocation of CPAP therapy.
study limitations
The study population was small due to the difficulty in 
recruiting nonobese OSA patients who are free of any con-
dition known to affect vascular endothelium. Over 70% of 
patients diagnosed with OSA in our Sleep Disorders Center 
have a BMI  30 and the majority have clinical evidence 
of cardiovascular disease. We did not study the capacity of 
EPC from OSA patients to form colonies in vitro. Reduced 
circulating EPC levels have been associated with ongo-
ing endothelial damage and reduced function of the EPC 
in vitro.10,44–46
Conclusions
In summary, OSA independently promotes endothelial 
apoptosis and impairs endothelial repair capacity. Enhanced 
endothelial apoptosis and impaired repair capacity may 
contribute to the high prevalence of vascular conditions in 
patients with OSA.
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Methods
Immunofluorescence for endothelial cell apoptosis
Endothelial cells were permeabilized in PBS/0.5% Triton 
X-100. Polyclonal anti-von Willebrand factor antibodies 
(DAKO, Glostrup, Denmark) were used, followed by Texas 
red-conjugated secondary antibodies to identify endothelial 
cells. Nuclei were stained with diaminophenylindole (DAPI) 
(Molecular Probes, Carlsbad, CA). Apoptotic cell nuclei were 
identified using in situ apoptosis peroxidase detection kit, 
the terminal deoxynucleotide transferase-mediated dUTP 
nick-end labeling (TUNEL) according to the manufacturer’s 
instruction (Intergen). Nucleated endothelial cells were iden-
tified by red (von Willebrand factor staining) and blue fluo-
rescence (DAPI DNA staining), and apoptosis was detected 
by green fluorescence (TUNEL). Apoptotic endothelial cells 
were detected by co-localized red and green fluorescence. 
Slides from study participants were stained concurrently 
with two slides of human umbilical venous endothelial cells 
(HUVEC) that served as positive and negative control. For 
negative controls, terminal deoxynucleotidyltransferase 
was omitted from the labeling mixture. For positive control, 
HUVEC slides were treated with DNase buffer for five 
minutes. Endothelial cells were analyzed with a fluores-
cent microscope under identical conditions (Nikon Eclipse 
E600, Melville, NY), and were captured by digital camera 
(Q Imaging Retiga EXi, Surrey, BC, Canada). The reader 
was blinded to subjects’ identity. Slides were systematically 
read left to right and top to bottom. The number of TUNEL-
positive endothelial cells was scored in 10 randomly chosen 
high-power fields.
Flow cytometry for circulating endothelial 
progenitor cells
Twelve mL of venous blood was withdrawn from a fore-
arm vein via the angiocath inserted for the endothelial 
harvesting. Mononuclear cells were isolated by density-
gradient centrifugation with Ficoll (Sigma) and counted 
using a Coulter Counter (Beckman Coulter, Fullerton, 
CA) within one hour of blood sample collection. One 
million mononuclear cells were aliquoted and incubated 
with 15 µL mouse serum (Sigma) at room temperature to 
block nonspecific binding of antibodies. Mononuclear cells 
were incubated for 30 minutes in the dark with monoclonal 
antibodies against human kinase insert domain receptor 
(KDR) which was phycoerythrin (PE)-labeled (10 µl; 
R&D Systems, Minneapolis, MN), and for 10 minutes 
with CD34 (fluorescein isothiocyanate [FITC]-labeled) 
(20 µl; Becton Dickinson), and CD133 (APC-labeled) 
(20 µl; Miltenyi, Auburn, CA). EPC were defined as cells 
positive for monoclonal antibodies against human KDR, 
CD34, and CD133.1–3 These bone-marrow-derived hemato-
poetic progenitor cells differentiate into mature endothelial 
cells and contribute to endothelial repair and new vessel 
formation after ischemic injury.3–6 Isotype-identical anti-
bodies IgG1-PE-FITC (Becton Dickinson) and IgG2b-APC 
(eBioscience, San Diego, CA) served as negative controls. 
Cell fluorescence was measured immediately after staining. 
FACSCalibur flow cytometer and CellQuest Software 
(Becton Dickinson) were used for data acquisition. Data 
were gated on the lymphocyte population, and 20,000 events 
were collected in the gated region for each sample.1 The 
percent of KDR+/CD34+/CD133+ cells was expressed as 
the percent of the gated events.
Flow cytometry for circulating endothelial  
apoptotic microparticles
Blood was collected in citrate tubes and processed within 
one hour of collection. Plasma derived from 10 mL of blood 
was centrifuged at 1000g for six minutes to generate plate-
let-poor plasma. 50 µL of plasma was incubated with 4 µL 
of PE-labeled monoclonal antibody against CD31 (Becton 
Dickinson) and 4 µL of FITC-labeled CD42b (Becton 
Dickinson), then diluted with 1 mL of PBS. PE-labeled IgG1 
and FITC-labeled IgG 2a (Pharmingen) served as a negative 
control. Particle detection was set to trigger by a fluorescent 
signal greater than background threshold. Data were gated 
using sizing of microparticles (forward light scatter) in the 
presence of calibrator beads. EMP were defined as par-
ticles 1.5 µm in size positive for monoclonal antibodies 
against CD31 and negative for CD42b.7 FACSCalibur flow 
cytometer (BD Biosciences) and CellQuest Software were 
used for data acquisition. Population of CD31+/CD42b- 
microparticles smaller than 1.5 µm is expressed as the 
number of EMP per µL of platelet poor plasma. Possible 
contamination with leukocytes microparticles (CD31+/
CD45+) was assessed. CD31+/CD45+ particles accounted 
for a negligible percentage of all CD31+ microparticles in 
samples from both patients with OSA and controls.
Brachial artery flow-mediated dilation
Vascular response in the brachial artery was assessed 
by FMD according to the guidelines of the International 
Brachial Artery Reactivity Task Force.8 Brachial artery 
diameter was measured in the contralateral arm to the 
endothelial harvesting site. Subjects were evaluated in a Vascular Health and Risk Management 2009:5 918
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Figure S1 Representative histograms of the flow cytometry analysis for endothelial apoptotic microparticles (EMP) from a control subject (Figure 1A) and a patient with OSA 
(Figure 1B). Particles were gated based on their size (forward light scatter) in the presence of calibrator beads [region 2 (R2)] A). EMP were defined as particles 1.5 µm 
in size positive for monoclonal antibodies against cD31 and negative for cD42b B). Isotype-identical antibodies served as negative controls C).Vascular Health and Risk Management 2009:5 919
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Figure S2 Representative histograms of the flow cytometry analysis for endothelial progenitor cells (EPC) from a control subject (Figure 2A) and a patient with OSA 
(Figure 2B). Mononuclear lymphocytic cell population was first gated from a plot of forward vs side scatter width [region 1(R1)]. A) Those cells were then gated for posi-
tive staining for kinase insert domain receptor (KDR) (R2). B) cells that stained positive for KDR were than gated for double positive staining for cD34 and cD133 (R3). 
C) The percent of KDR+/cD34+/cD133+ cells was expressed as the percent of the gated events, D) Isotype-identical antibodies IgG1-PE, E) and IgG1-FITC and IgG2b-APC 
F) served as negative controls. Reproducibility of the measurements was assessed by obtaining two separate blood samples from eight control subjects on days 0 and 28. 
The overall coefficient of variation between the two measurements was 10%.Vascular Health and Risk Management 2009:5
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quiet, temperature-controlled room. After a 30-minute 
rest in a supine position, the brachial artery diameter was 
measured 6 cm proximal to the antecubital fossa using a 
7–15 MHz linear array transducer (Philips 5500, Andover, 
MA). Occlusion blood pressure cuff was placed over the 
proximal forearm just below the antecubital fossa. FMD 
was measured as the dilator response to reactive hyperemia 
induced by a five-minute blood pressure cuff occlusion of the 
upper arm. The cuff was inflated to 50 mm Hg above systolic 
blood pressure if the systolic blood pressure was greater than 
150 mm Hg, or to 200 mm Hg if the systolic blood pres-
sure was less than 150 mm Hg. Systolic blood pressure was 
lower than 150 mm Hg in all study participants. Brachial 
artery diameter (expressed in millimeters up to one decimal 
place) was measured at rest and during peak hyperemia for 
one minute after a five-minute occlusion of arterial flow. 
A blinded reader analyzed brachial artery diameters off-line 
using analysis software. The percent diameter change for 
FMD was calculated as follows:
FMD (%) = [(brachial artery diameter at peak hyperemia  
  - diameter at rest)/diameter at rest] × 100.
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